New drug approach offers hope for patients with recurrent aggressive cancers
A new treatment for endometrial cancer, sacituzumab tirumotecan (sac-TMT), has shown promising results in a Phase 3 clinical trial. The drug demonstrated statistically significant improvements in overall survival and progression-free survival compared to traditional chemotherapy. This marks a significant advancement in targeted cancer therapies for patients with advanced or recurrent endometrial cancer.
- ▪The TroFuse-005 trial involved 776 patients with endometrial cancer who had previously received chemotherapy and immunotherapy.
- ▪Patients receiving sac-TMT showed clinically meaningful improvements in their disease state compared to those on physician's choice treatments.
- ▪Sac-TMT is the first antibody-drug conjugate to achieve significant survival improvements in this patient population.
Opening excerpt (first ~120 words) tap to expand
Health New drug approach offers hope for patients with recurrent aggressive cancers Endometrial cancer patients saw improved survival when taking sac-TMT in clinical trials By Angelica Stabile Fox News Published May 20, 2026 7:00am EDT Facebook Twitter Threads Flipboard Comments Print Email Add Fox News on Google close Video Colorectal cancer survivor says symptoms were dismissed for years before diagnosis Marisa Peters, 44, a Los Angeles mother of three, shares the alarming warning signs that were chalked up to pregnancy for years before her stage 3 diagnosis. NEWYou can now listen to Fox News articles! A new treatment for endometrial cancer demonstrated strong potential in a Phase 3 clinical trial.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Fox News.
Discussion
0 commentsMore from Fox News
